- Report
- September 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- September 2025
- 83 Pages
Global
From €3500EUR$4,178USD£3,179GBP
- Report
- November 2021
- 40 Pages
China
From €2333EUR$2,600USD£2,048GBP
- Report
- February 2024
- 110 Pages
Global
From €4262EUR$4,750USD£3,741GBP
- Report
- August 2024
- 123 Pages
China
From €1615EUR$1,800USD£1,418GBP
- Report
- January 2024
- 129 Pages
United States
€3410EUR$3,800USD£2,993GBP
- Report
- November 2025
- 50 Pages
Global
From €2378EUR$2,650USD£2,087GBP
- Report
- August 2024
- 244 Pages
China
From €3589EUR$4,000USD£3,150GBP
Bicalutamide is a non-steroidal anti-androgen drug used in the treatment of prostate cancer. It is used in combination with a luteinizing hormone-releasing hormone (LHRH) agonist, such as leuprolide, to reduce the production of testosterone in the body. This helps to slow the growth of prostate cancer cells. Bicalutamide is also used as a monotherapy for advanced prostate cancer, where it can reduce the size of the tumor and slow the progression of the disease.
Bicalutamide is available in both oral and injectable forms, and is generally well tolerated with few side effects. Common side effects include hot flashes, nausea, and fatigue.
The bicalutamide market is highly competitive, with several major players offering a range of products. These include AstraZeneca, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Other companies in the market include Dr. Reddy's Laboratories, Lupin Pharmaceuticals, and Cipla. Show Less Read more
